What is HC Wainwright’s Estimate for MAZE Q2 Earnings?

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Stock analysts at HC Wainwright issued their Q2 2027 earnings per share estimates for Maze Therapeutics in a report issued on Monday, October 5th. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.65) per share for the quarter. HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q3 2027 earnings at ($0.65) EPS.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76).

A number of other equities research analysts have also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Wedbush reiterated an “outperform” rating and issued a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Citigroup started coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 price target on the stock. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Stock Down 0.7%

MAZE stock opened at $26.25 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.42 and a beta of 2.16. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The stock has a fifty day moving average of $26.88 and a 200-day moving average of $27.57.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after acquiring an additional 465,641 shares during the period. TRV GP IV LLC bought a new stake in Maze Therapeutics during the 2nd quarter worth approximately $133,502,907. ARCH Venture Management LLC bought a new stake in Maze Therapeutics during the 2nd quarter worth approximately $122,983,582. BlackRock Inc. purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $104,525,000. Finally, Jupiter Topco LLC purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $101,764,000.

Insider Buying and Selling

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares in the company, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 16,141 shares of Maze Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $26.93, for a total value of $434,677.13. Following the transaction, the chief marketing officer directly owned 16,141 shares of the company’s stock, valued at $434,677.13. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 192,991 shares of company stock valued at $5,152,084. 5.30% of the stock is owned by company insiders.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple EPS forecasts. The firm improved its estimates for Q3 2026 to a loss of $0.70 per share from $0.77, Q4 2026 to a loss of $0.71 from $0.80, FY2026 to a loss of $2.63 from $2.81, FY2027 to a loss of $2.60 from $3.27, FY2028 to a loss of $2.23 from $2.89, and FY2029 to a loss of $2.05 from $2.46. Although Maze is still expected to report losses, the revisions suggest expectations for narrower losses and may support investor sentiment. MAZE Stock Gets Increased EPS Forecast from HC Wainwright
• Positive Sentiment: The analyst maintained a Buy rating and $110 price target. HC Wainwright’s target implies substantial upside relative to Maze’s recent trading level, reflecting confidence in the company’s pipeline and longer-term commercial potential. Maze Therapeutics analyst coverage
• Neutral Sentiment: Maze will present clinical and preclinical kidney-disease data at ASN Kidney Week. An oral presentation will feature previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, while posters will discuss preclinical work supporting MZE782 and SLC6A19 inhibition. The October 21–25 event could provide additional visibility into the programs, though the announcement did not include new efficacy results. Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
• Negative Sentiment: HC Wainwright sharply reduced its FY2030 EPS forecast to a loss of $2.16 per share from a loss of $0.72. The downgrade contrasts with the nearer-term improvements and highlights uncertainty around Maze’s long-term path to profitability. The consensus forecast remains a loss of $2.72 per share for the current year.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.